Search results
Results from the WOW.Com Content Network
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
This is a general overview and status of places affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes coronavirus disease 2019 and is responsible for the COVID-19 pandemic. The first human cases of COVID-19 were identified in Wuhan, the capital of the province of Hubei in China in December 2019. It ...
The first section contains summary information: the total number of countries and territories with at least 100, 1,000, 10,000, 100,000, a million and ten million cases; the number of cases reported to WHO; the countries and territories that have reported no cases yet to WHO; and two charts showing the 20 countries and territories with the ...
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
During the COVID-19 pandemic, there has been interest in vitamin D status and supplements, given the significant overlap in the risk factors for severe COVID-19 and vitamin D deficiency. [196] These include obesity, older age, and Black or Asian ethnic origin, and it is notable that vitamin D deficiency is particularly common within these groups.
By March 26, 2020, the United States, with the world's third-largest population, surpassed China and Italy as the country with the world's highest number of confirmed cases. [86] By April 25, the U.S. had more than 905,000 confirmed coronavirus cases and nearly 52,000 deaths, giving it a mortality rate around 5.7 percent.
The COVID-19 pandemic has had many impacts on global health beyond those caused by the COVID-19 disease itself. It has led to a reduction in hospital visits for other reasons. There have been 38 per cent fewer hospital visits for heart attack symptoms in the United States and 40 per cent fewer in Spain. [1]
In unvaccinated high-risk people with COVID‑19, nirmatrelvir/ritonavir can reduce the risk of hospitalization or death by 88% if taken within five days of symptom onset. [154] People who take nirmatrelvir/ritonavir also test negative for COVID‑19 about two and a half days earlier than people who do not. [155]